Skip to main content
Erschienen in: Breast Cancer 4/2016

30.05.2015 | Original Article

Willingness of Japanese patients with breast cancer to have genetic testing of BRCA without burden of expenses

verfasst von: Hiroshi Nakagomi, Ikuko Sakamoto, Yosuke Hirotsu, Kenji Amemiya, Hitoshi Mochizuki, Masayuki Inoue, Satoko Nakagomi, Takeo Kubota, Masao Omata

Erschienen in: Breast Cancer | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Genetic analysis for individuals who are at risk for hereditary breast and ovarian cancer syndrome (HBOC) has becoming widely accepted. The poor introduction of the genetic testing of BRCA in Japan compared with western countries could be due to insufficient recognition of its importance, prejudice against a heredity disease, especially in non-urban districts, and its high cost. There is few available data regarding the acceptance or willingness to have genetic testing among Japanese who are at risk and living outside Tokyo.

Methods

Of 670 patients seen and detailed family history taken at our hospital, located non-urban, 30 (4 %) gave the family history of breast cancer in more than 2 members within the second degree relatives (“stronger” family history group), 92 (14 %) in 1 member (“weaker” group), and 548 (82 %) in none of members (“sporadic” group). Then, we selected 107 (24 from “stronger”, 50 from “weaker”, 33 from “sporadic” family history group) to see if they are willing to receive cost-free genetic testing of BRCA 1 and BRCA2.

Results

Ninety-two of 107 (86 %) patients agreed and 15 (14 %) refused. The rate of refusal for BRCA testing was higher in “stronger family history group” (6/24, 25 %) compared to “weaker” (7/50, 14 %) or “sporadic” (2/33, 6 %) (p = 0.04), respectively.

Conclusions

These data indicate that the currently available preventive measures and/or counseling system may not be sufficient enough to convince the high risk population to receive the genetic testing or to overcome the prejudice in non-urban area in Japan, even if served free.
Literatur
3.
Zurück zum Zitat Melchor L, Benitez J. The complex genetic landscape of familial breast cancer. Hum Genet. 2013;132:845–63.CrossRefPubMed Melchor L, Benitez J. The complex genetic landscape of familial breast cancer. Hum Genet. 2013;132:845–63.CrossRefPubMed
4.
Zurück zum Zitat Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.CrossRefPubMedPubMedCentral Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Bowless JM, Eggingto KR, Moyes K, et al. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clini Genet. 2013;. doi:10.11111/cge.12315. Bowless JM, Eggingto KR, Moyes K, et al. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clini Genet. 2013;. doi:10.​11111/​cge.​12315.
7.
Zurück zum Zitat Hirotsu Y, Nakagomi H, Sakamoto I, et al. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol Genet Genomic Med. 2015;3:121–9.CrossRefPubMed Hirotsu Y, Nakagomi H, Sakamoto I, et al. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol Genet Genomic Med. 2015;3:121–9.CrossRefPubMed
8.
Zurück zum Zitat Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.CrossRefPubMed Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.CrossRefPubMed
9.
Zurück zum Zitat Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–92.CrossRefPubMed Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–92.CrossRefPubMed
10.
Zurück zum Zitat Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480–90.CrossRefPubMed Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480–90.CrossRefPubMed
11.
Zurück zum Zitat King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:2251–6.CrossRefPubMed King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:2251–6.CrossRefPubMed
12.
Zurück zum Zitat Duffy SW, Nixon RM. Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. Br J Cancer. 2002;86:218–21.CrossRefPubMedPubMedCentral Duffy SW, Nixon RM. Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. Br J Cancer. 2002;86:218–21.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ‘t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055–62.CrossRefPubMed Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ‘t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055–62.CrossRefPubMed
14.
Zurück zum Zitat Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26:1093–7.CrossRefPubMed Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26:1093–7.CrossRefPubMed
15.
Zurück zum Zitat Arai M, Utsunomiya J, Miki Y. Familial breast and ovarian cancers. Int J Clin Oncol. 2004;9:270–82.CrossRefPubMed Arai M, Utsunomiya J, Miki Y. Familial breast and ovarian cancers. Int J Clin Oncol. 2004;9:270–82.CrossRefPubMed
16.
Zurück zum Zitat Bando H. Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan. Breast Cancer. 2014;21:656–63.CrossRefPubMed Bando H. Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan. Breast Cancer. 2014;21:656–63.CrossRefPubMed
17.
Zurück zum Zitat Bando H, Shimizu C,Yamamoto S, Mizota Y, Katou T. Current situation Survay on provision of information about hereditary breast by Japanese physician to young breast cancer patients (abstract) J Japan Soc Clin Oncol. 2011;452;MS1–6. Bando H, Shimizu C,Yamamoto S, Mizota Y, Katou T. Current situation Survay on provision of information about hereditary breast by Japanese physician to young breast cancer patients (abstract) J Japan Soc Clin Oncol. 2011;452;MS1–6.
18.
Zurück zum Zitat Genetic Information Non-Discrimination Act of 2008. H.R. 493, 110th Cong:2007–2008. Genetic Information Non-Discrimination Act of 2008. H.R. 493, 110th Cong:2007–2008.
19.
Zurück zum Zitat Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25:32–40.CrossRefPubMed Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25:32–40.CrossRefPubMed
20.
Zurück zum Zitat Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852–61.CrossRefPubMed Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852–61.CrossRefPubMed
21.
Zurück zum Zitat Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–92.CrossRefPubMed Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–92.CrossRefPubMed
22.
Zurück zum Zitat Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852–61.CrossRefPubMed Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852–61.CrossRefPubMed
Metadaten
Titel
Willingness of Japanese patients with breast cancer to have genetic testing of BRCA without burden of expenses
verfasst von
Hiroshi Nakagomi
Ikuko Sakamoto
Yosuke Hirotsu
Kenji Amemiya
Hitoshi Mochizuki
Masayuki Inoue
Satoko Nakagomi
Takeo Kubota
Masao Omata
Publikationsdatum
30.05.2015
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 4/2016
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-015-0618-7

Weitere Artikel der Ausgabe 4/2016

Breast Cancer 4/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.